Project Grant R44CA080584

This Project Grant award of $441,522 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research CFDA program supports research to reduce the need for systemic immunosuppression in kidney transplant patients. The objective is to test the efficacy and safety of pre-transplant modification of the kidney graft with a small molecule integrin inhibitor, delivered via ex vivo perfusion, to decrease immune cell recruitment and improve...

This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to evaluate the use of serum microRNA (miRNA) profiling to assist in the safe tapering of immunosuppression for liver transplant recipients. The $264,596 award will support a 3-phase study design to establish trial procedures, develop the protocol, and assess outcome measures. The research team, led by The...

The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $300,000 Project Grant to Electronic Biosciences, Inc. to develop a novel point-of-care technology for monitoring immunosuppressant drug levels. The key product being developed is a portable, fingerstick-based testing system that can provide convenient and frequent immunosuppressant drug level measurements. This will enable more precise dosing for...

The federal Project Grant award of $3,106,301 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate the mechanisms underlying induction and maintenance of immunosuppression and the impact on T cell function after kidney transplantation. The project aims to analyze epigenetic, transcriptional, and immune phenotype changes associated with the use of antithymocyte globulin (ATG)...

This $210,867 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a cell-based therapy for generating donor-specific immune tolerance in kidney transplant recipients. The project will engineer "push/pull" particle-loaded tolerogenic dendritic cells (PPP-TolDCs) that can be infused into donor kidneys prior to transplantation. These engineered PPP-TolDCs...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research at New York University (NYU) to develop personalized immunosuppression regimens for kidney transplant recipients. The $847,371 award, with a project period from September 15, 2025 to July 31, 2030, will leverage a large nationwide electronic health record database to...

Novelmed Therapeutics, Inc. was awarded a $900,000 Project Grant from the National Institutes of Health's National Institute on Aging to develop a selective inhibitor of the alternative pathway of complement as a treatment for Neuromyelitis Optica Spectrum Disorder. Under the grant, Novelmed will conduct preclinical studies to evaluate its lead drug candidate NM5072, including in vitro and ex vivo assays to confirm the drug's mechanism of action and selective inhibition of the alternative...

The University of Pittsburgh received a $679,937 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to conduct research on mechanisms and therapeutic targeting of T cell regulation in heart allograft recipient monkeys. The 5-year project aims to investigate the impact of cytokine modulation and administration of novel, donor-specific chimeric antigen receptor regulatory T cells (CARTREG) on promoting long-term...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $305,855 to Aleutian Therapeutics, Inc. to develop a novel gene editing platform that enables allogeneic pluripotent stem cell (PSC) therapies to evade host immune system recognition. The goal is to overcome key barriers to making PSC-based regenerative therapies, such as those for type 1 diabetes, more...

This Project Grant award of $402,500 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to evaluate the use of anti-CD154 monoclonal antibody therapy in a nonhuman primate vascularized composite allograft (VCA) model. The research aims to determine the efficacy of this approach in regulating the host immune response and promoting transplantation tolerance, particularly in sensitized...